The rationale of this strategy is based on the fact that mTOR inhibition will block the downstream oncogenic targets of mTOR signaling proteins including S6K and 4E-BP1 which are critically involved in cancer cell protein synthesis and proliferation [19]. This evidence concerns the gene EIF4EBP1 and cancer.